መነሻ › ክሮኒክ ሊምፎሳይቲክ ሉኬሚያ › Wisconsin › Milwaukee
በMilwaukee፣ WI ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች
ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ 15 ጥናቶች በMilwaukee እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።
Official study text (English)
ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
ተሳታዮችን በመፈለግ ላይደረጃ 3
- UW Cancer Center at ProHealth Care, Waukesha · 17 ማይል ርቀት
- ProHealth D N Greenwald Center, Mukwonago · 25 ማይል ርቀት
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- እና 9 ተጨማሪ
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Medical College of Wisconsin, Milwaukee
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Medical College of Wisconsin, Milwaukee
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
ተሳታዮችን በመፈለግ ላይደረጃ 2
- The Medical College of Wisconsin, Milwaukee
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
ተሳታዮችን በመፈለግ ላይደረጃ 1
- Medical College of Wisconsin, Milwaukee
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
ተሳታዮችን በመፈለግ ላይደረጃ 1
- Medical College of Wisconsin, Milwaukee
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
ተሳታዮችን በመፈለግ ላይደረጃ 2
- Medical College of Wisconsin, Milwaukee
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 4
- Medical College of Wisconsin, Milwaukee
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
ተሳታዮችን በመፈለግ ላይደረጃ 4
- Medical College of Wisconsin, Milwaukee
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
- Medical College of Wisconsin and Froedtert Hospital, Milwaukee
Study of SGR-1505 in Mature B-Cell Neoplasms
ተሳታዮችን በመፈለግ ላይደረጃ 1
- Medical College of Wisconsin, Milwaukee
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
ተሳታዮችን በመፈለግ ላይደረጃ 1
- The Medical College of Wisconsin, Milwaukee
Long-term Follow-up Study of Patients Receiving CAR-T Cells
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
- Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee
በሌሎች ከተሞች ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ ጥናቶች
- Boston, MA31 ጥናቶች
- Columbus, OH28 ጥናቶች
- Durham, NC27 ጥናቶች
- Washington, DC22 ጥናቶች
- Seattle, WA20 ጥናቶች
- Rochester, MN19 ጥናቶች
- New York City, NY18 ጥናቶች
- Houston, TX17 ጥናቶች
- Baldwin Park, CA16 ጥናቶች
- Cincinnati, OH14 ጥናቶች
- Chicago, IL14 ጥናቶች
- Nashville, TN13 ጥናቶች
በMilwaukee ውስጥ ያሉ ሌሎች ጥናቶች
- የጡንቻ ካንሰር23 ጥናቶች
- ኖን-ስማል ሴል የሳንባ ካንሰር22 ጥናቶች
- ካንሰር (ሁሉም ዓይነቶች)22 ጥናቶች
- የሳንባ ካንሰር21 ጥናቶች
- Multiple Myeloma21 ጥናቶች
- የፕሮስቴት ካንሰር20 ጥናቶች
- ፎሊኩላር ሊምፎማ19 ጥናቶች
- የፓንክሪያስ ካንሰር18 ጥናቶች
- ኖን-ሆጅኪን ሊምፎማ18 ጥናቶች
- የእንቁላል ካንሰር17 ጥናቶች
- አኩት ማይሎይድ ሊውኬሚያ17 ጥናቶች
- በርኪት ሊምፎማ16 ጥናቶች
ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።